Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes of NSCLC patients with better overall survival. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.